Aphidicolin

Aphidicolin

SCHEMBL16610406

C[C@]1(CO)C2CC[C@H]3CC4C[C@]3(CC[C@]4(O)CO)[C@@]2(C)CC[C@H]1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLA1 P09884 7/20 1.00
LMNA P02545 2/20 1.00
HTT P42858 1/20 1.00
RECQL P46063 1/20 1.00
SMN1; SMN2 Q16637 1/20 1.00
HIF1A Q16665 1/20 1.00
CYP2C19 P33261 1/20 0.70
CYP3A4 P08684 2/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
ALOX5 P09917 1/20 0.33
PTPN1 P18031 2/20 0.33
TOP2A P11388 1/20 0.33
HSD11B1 P28845 2/20 0.32
F3 P13726 3/20 0.31
CES2 O00748 1/20 0.31
CES1 P23141 1/20 0.31
USP2 O75604 1/20 0.31
USP7 Q93009 1/20 0.31
SLCO1B3 Q9NPD5 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Aphidicolin SCHEMBL14667945 1.00 POLA1 (1.00) POLA1LMNAHTTRECQLSMN1; SMN2
Aphidicolin SCHEMBL183956 1.00 POLA1 (1.00) POLA1LMNAHTTRECQLSMN1; SMN2
Aphidicolin SCHEMBL8763668 1.00 POLA1 (1.00) POLA1LMNAHTTRECQLSMN1; SMN2
SCHEMBL14552897 0.84 LMNA (0.73) POLA1LMNAHTTRECQLSMN1; SMN2
Hydrochloric Acid SCHEMBL29351943 0.82 CYP2C19 (0.98) POLA1LMNAHTTRECQLSMN1; SMN2
Aphidicolin SCHEMBL2332951 0.77 POLA1 (0.59) POLA1LMNAHTTRECQLSMN1; SMN2
SCHEMBL15747 0.76 CYP2C19 (0.70) POLA1LMNAHTTRECQLSMN1; SMN2
Temoporfin SCHEMBL8660214 0.73 POLA1 (0.54) POLA1LMNAHTTRECQLSMN1; SMN2
SCHEMBL29483361 0.72 LMNA (0.56) POLA1LMNAHTTRECQLSMN1; SMN2
Stemodin SCHEMBL15978379 0.64 LMNA (0.47) POLA1LMNAHTTRECQLSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150093371-A1 ANTIVIRAL COMPOSITIONS AND METHODS OF THEIR USE Humanitas Technology, LLC (US) 2015-04-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150093371-A1 ANTIVIRAL COMPOSITIONS AND METHODS OF THEIR USE DDX5, MAVS, EIF2AK2 POLA1 1649/4885LMNA 3080/4885HTT 3620/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.